Navamedic ASA NAVA
OSL · Norway · Distribution Services
NOK 13.50-0.25 (-1.82%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Navamedic ASA (OSE: NAVA) today announces the launch of Virono®, the first over-the-counter single-dose treatment for recurrent cold sores (herpes labialis) in adults. The launch establishes a new OTC treatment category and represents an important step in Navamedic's Nordic Consumer Health growth strategy. Virono is available in Swedish pharmacies from May 2026. Roll-out activities have also been initiated in Finland, while launch in the Netherlands is planned later in 2026.
Amid ongoing geopolitical tensions and fluctuating energy prices, European markets have experienced mixed performance, with the pan-European STOXX Europe 600 Index seeing a modest gain. In this uncertain environment, identifying stocks trading below their estimated fair value can present potential opportunities for investors seeking to capitalize on market inefficiencies.
As the European markets navigate through a period of uncertainty driven by geopolitical tensions in the Middle East and fluctuating energy prices, key indices like the STOXX Europe 600 have shown modest gains, reflecting cautious optimism among investors. In this environment, identifying stocks that may be trading below their fair value estimates can offer potential opportunities for investors seeking to capitalize on market inefficiencies.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.